BCIQ Profiles

Company Profile Report
1109 lilly covid eua
BioCentury & Getty Images


EUA for Lilly, AbCellera COVID mAb despite Phase II miss for authorized dose

Nov 10, 2020 | 3:30 AM GMT

FDA’s first emergency use authorization for a SARS-CoV-2-targeting mAb covers the lowest dose of Lilly and AbCellera’s candidate to treat COVID-19 outpatients, a dose that was not

Read the full 534 word article

How to gain access

Continue reading with a
two-week free trial.